| 29 Dec 2009 |
Director/PDMR Shareholding |
| 23 Dec 2009 |
Dr Michael Rosenblatt to step down as non-executive director |
| 22 Dec 2009 |
Shire Submits Biologics License Application (BLA) for REPLAGAL® with the U.S. Food and Drug Administration (FDA) |
| 21 Dec 2009 |
Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter™ Page |
| 16 Dec 2009 |
Membership of Board Committees |
| 16 Dec 2009 |
Director/PDMR Shareholding |
| 14 Dec 2009 |
Director/PDMR Shareholding |
| 11 Dec 2009 |
Director/PDMR Shareholding (18KB PDF) |
| 07 Dec 2009 |
Notification of major interests in shares (32KB PDF) |
| 04 Dec 2009 |
Non-safety-related voluntary recall of a limited portion of Daytrana® (methylphenidate transdermal system) patches announced |
| 02 Dec 2009 |
Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic |
| 01 Dec 2009 |
Total Voting Rights |
| 24 Nov 2009 |
Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease |
| 23 Nov 2009 |
Block listing six monthly return (25KB PDF) |
| 12 Nov 2009 |
PDMR Shareholding |
| 12 Nov 2009 |
Shire Reports Findings From an Analysis Examining Emotional Lability in Children With ADHD Taking VYVANSE® (lisdexamfetamine dimesylate) Capsules CII |
| 11 Nov 2009 |
Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse® (lisdexamfetamine dimesylate) Capsules CII |
| 04 Nov 2009 |
FDA Grants Priority Review for Shire’s velaglucerase alfa for Type 1 Gaucher Disease |
| 03 Nov 2009 |
Directors/PDMR Shareholding |
| 02 Nov 2009 |
Total Voting Rights |
| 02 Nov 2009 |
New Shire Board member |
| 30 Oct 2009 |
Shire Reports Tolerability and Clinical Effects Results of DAYTRANA® (methylphenidate transdermal system) from Study in Adolescents with ADHD |
| 30 Oct 2009 |
Shire continues to deliver excellent growth from core products (354KB PDF) |
| 28 Oct 2009 |
Shire Secures European Wide Label Extension for FOSRENOL® in Chronic Kidney Disease |
| 26 Oct 2009 |
FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity |
| 22 Oct 2009 |
Third quarter 2009 results date notification – October 30, 2009 |
| 21 Oct 2009 |
Shire Targets Fourth Quarter Filing of BLA for REPLAGAL® for Fabry Disease with U.S. FDA |
| 19 Oct 2009 |
Shire voluntarily enables further access to HIV/AIDS medicines for Rwanda |
| 15 Oct 2009 |
Holding(s) in Company (33KB PDF) |
| 13 Oct 2009 |
Shire and Sandoz Settle All Pending Litigation Concerning ADDERALL XR® |
| 07 Oct 2009 |
Data from a head-to-head crossover study evaluating FOSRENOL® and sevelamer published today |
| 01 Oct 2009 |
Total Voting Rights (16KB PDF) |
| 25 Sep 2009 |
Director/PDMR Shareholding |
| 22 Sep 2009 |
Director/PDMR Shareholding |
| 18 Sep 2009 |
Director/PDMR Shareholding |
| 16 Sep 2009 |
Celebrity dancer, Karina Smirnoff, speaks out for the first time on how ADHD has impacted her life |
| 08 Sep 2009 |
Update on velaglucerase alfa |
| 04 Sep 2009 |
Director/PDMR Shareholding |
| 03 Sep 2009 |
Director/PDMR Shareholding |
| 01 Sep 2009 |
Total Voting Rights |
| 01 Sep 2009 |
Elections for interim dividend in respect of the six months to June 30, 2009 |
| 01 Sep 2009 |
Shire Completes Submission of NDA for velaglucerase alfa for Type 1 Gaucher disease and Reports Positive Results for Remaining Two Phase III Trials |
| 24 Aug 2009 |
Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform |
| 21 Aug 2009 |
Half Yearly Report |
| 19 Aug 2009 |
Director/PDMR Shareholding (19KB PDF) |
| 17 Aug 2009 |
Shire Initiates Two Adult ADHD Outreach Programs |
| 07 Aug 2009 |
Membership of Board Committees |
| 05 Aug 2009 |
Q2 results - Core portfolio of products delivers 20% sales growth (291KB PDF) |
| 03 Aug 2009 |
Total Voting Rights |
| 03 Aug 2009 |
Shire Reports Positive Results from First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions with FDA |
| 22 Jul 2009 |
Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse® (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration |
| 21 Jul 2009 |
Second quarter 2009 results date notification – August 5, 2009 |
| 16 Jul 2009 |
Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease |
| 16 Jul 2009 |
Message from Sylvie Grégoire, President, Human Genetic Therapies regarding the MLD experimental drug |
| 08 Jul 2009 |
Dr Jeffrey Leiden appointed to Vertex Board. |
| 06 Jul 2009 |
Shire has filed a treatment protocol for velaglucerase alfa for Gaucher Disease |
| 01 Jul 2009 |
Total Voting Rights |
| 01 Jul 2009 |
Study Showed VYVANSE® (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment |
| 16 Jun 2009 |
New Study in Women with Fabry Disease, Demonstrates Significant Benefits of Treatment with REPLAGAL® (agalsidase alfa) 0.2mg/kg on Kidney Function, Heart Function and Burden of Disease |
| 01 Jun 2009 |
Total Voting Rights |
| 01 Jun 2009 |
FDA Approves Labeling Change for VYVANSE® (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD (36KB PDF) |
| 26 May 2009 |
Block Listing Six Monthly Return (26KB PDF) |
| 22 May 2009 |
Director/PDMR Shareholding |
| 22 May 2009 |
New Study Evaluating the ADHD Medication VYVANSE® (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC® 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) |
| 21 May 2009 |
Results from a European Caregiver Survey Highlight the Impact of Attention Deficit Hyperactivity Disorder (ADHD) on the Child and the Family |
| 15 May 2009 |
Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18 |
| 12 May 2009 |
Director/PDMR Shareholding (18KB PDF) |
| 01 May 2009 |
Total Voting Rights |
| 30 Apr 2009 |
Shire begins the year with a strong performance (175KB PDF) |
| 28 Apr 2009 |
Results of the Annual General Meeting held on April 28, 2009 (20KB PDF) |
| 20 Apr 2009 |
First quarter 2009 results date notification – April 30, 2009 |
| 02 Apr 2009 |
Shire files lawsuit against Natco Pharma for infringement of FOSRENOL® (lanthanum carbonate) patents |
| 01 Apr 2009 |
Annual Information Update (28KB PDF) |
| 01 Apr 2009 |
Director/PDMR Shareholding (19KB PDF) |
| 01 Apr 2009 |
Notification of major interest in shares (90KB PDF) |
| 01 Apr 2009 |
Total Voting Rights |
| 31 Mar 2009 |
Shire and GlaxoSmithKline enter agreement to co-promote VYVANSE® (lisdexamfetamine dimesylate) CII for the treatment of adults with ADHD |
| 25 Mar 2009 |
Publication of Shire plc's Annual Report 2008 (161KB PDF) |
| 21 Mar 2009 |
Saving a playground, lifting a neighborhood |
| 20 Mar 2009 |
Shire files lawsuit against Mylan for infringement of FOSRENOL® (lanthanum carbonate) patent |
| 20 Mar 2009 |
Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA® (methylphenidate transdermal system) patches announced |
| 19 Mar 2009 |
Holding(s) in Company (32KB PDF) |
| 16 Mar 2009 |
Shire files lawsuit against Barr Laboratories for infringement of FOSRENOL® (lanthanum carbonate) patents |
| 16 Mar 2009 |
Shire withdraws European Application for DAYTRANA™ (methylphenidate transdermal system) |
| 12 Mar 2009 |
World Kidney Day press release |
| 12 Mar 2009 |
Holding(s) in Company (33KB PDF) |
| 09 Mar 2009 |
Holding(s) in Company (31KB PDF) |
| 05 Mar 2009 |
Holding(s) in Company (34KB PDF) |
| 02 Mar 2009 |
Elections for interim dividend in respect of the six months to December 31, 2008 |
| 02 Mar 2009 |
Total Voting Rights |
| 26 Feb 2009 |
Shire HGT Announces Support for Rare Disease Day |
| 23 Feb 2009 |
Director/PDMR Shareholding |
| 23 Feb 2009 |
Director/PDMR Shareholding |
| 20 Feb 2009 |
Shire to enter European ADHD market with the acquisition of EQUASYM® IR and XL |
| 20 Feb 2009 |
Shire Announces Opening of Office in Japan |
| 19 Feb 2009 |
Shire delivers excellent growth for the year, with the new product portfolio achieving sales of $1 billion |
| 09 Feb 2009 |
Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan |
| 09 Feb 2009 |
Full Year 2008 results date notification – 19 February 2009 |
| 05 Feb 2009 |
Change to Director's details |
| 02 Feb 2009 |
Total Voting Rights |
| 05 Jan 2009 |
Total Voting Rights |
